DelveInsight’s, “Frontotemporal Dementia Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Frontotemporal Dementia Emerging drugs, the Frontotemporal Dementia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Frontotemporal Dementia pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Frontotemporal Dementia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Frontotemporal Dementia clinical trials studies, Frontotemporal Dementia NDA approvals (if any), and product development activities comprising the technology, Frontotemporal Dementia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Frontotemporal Dementia Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Frontotemporal Dementia Pipeline landscape @ Frontotemporal Dementia Pipeline Outlook Report
Frontotemporal Dementia Overview
Frontotemporal dementia is an uncommon type of dementia that causes problems with behaviour and language. Dementia is the name for problems with mental abilities caused by gradual changes and damage in the brain. Frontotemporal dementia affects the front and sides of the brain (the frontal and temporal lobes).Dementia mostly affects people over 65, but frontotemporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, frontotemporal dementia tends to develop slowly and get gradually worse over several years.
Recent Developmental Activities in the Frontotemporal Dementia Treatment Landscape
For further information, refer to the detailed Frontotemporal Dementia Drugs Launch, Frontotemporal Dementia Developmental Activities, and Frontotemporal Dementia News, click here for Frontotemporal Dementia Ongoing Clinical Trial Analysis
Frontotemporal Dementia Emerging Drugs Profile
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.
AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK.
Passage Bio, gene therapy product candidate, PBFT02, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently the product is in Phase I/II for the treatment of Frontotemporal Dementia.
WVE-004 is an investigational variant-selective silencing candidate designed to selectively target the transcript variants containing a hexanucleotide repeat expansion (G4C2) in the C9orf72 gene, while sparing the healthy C9orf72 protein. G4C2 expansions are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.
EXO 050, is the lead drug candidate of Coya Therapeutics for the treatment of FTD.Currently, the drug is in Pre-Clinical stage of development for the treatment of FTD.
Frontotemporal Dementia Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Frontotemporal Dementia. The companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.
Find out more about the Frontotemporal Dementia Pipeline Segmentation, Therapeutics Assessment, and Frontotemporal Dementia Emerging Drugs @ Frontotemporal Dementia Treatment Landscape
Scope of the Frontotemporal Dementia Pipeline Report
Dive deep into rich insights for drugs for Frontotemporal Dementia Pipeline Companies and Therapies, click here @ Frontotemporal Dementia Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Frontotemporal Dementia Mergers and acquisitions, Frontotemporal Dementia Licensing Activities @ Frontotemporal Dementia Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/